ACANYA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ACANYA (ACANYA).
Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.
| Metabolism | Clindamycin is metabolized primarily by the liver via CYP3A4. Benzoyl peroxide is metabolized to benzoic acid and then excreted in urine. |
| Excretion | Acanya (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% gel) is a fixed-dose combination applied topically. Systemic absorption is minimal. Clindamycin: <0.1% of applied dose excreted renally as parent and metabolites. Benzoyl peroxide: metabolized to benzoic acid, which is conjugated and excreted renally; <5% of applied dose appears in urine. Fecal excretion is negligible. |
| Half-life | Clindamycin: after topical application, terminal half-life is approximately 2-3 hours in serum, but clinical relevance is minimal due to low systemic levels. Benzoyl peroxide metabolites have a half-life of ~1-2 hours. The clinical effect is primarily local with sustained antimicrobial and keratolytic activity. |
| Protein binding | Clindamycin: ~60-94% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). Benzoyl peroxide: not significantly bound; its metabolite benzoic acid is ~35% bound to albumin. |
| Volume of Distribution | After topical application, systemic concentrations are negligible; Vd not applicable for parent compound. For clindamycin after intravenous administration, Vd is ~0.6-1.2 L/kg. For benzoyl peroxide, dermal penetration is limited to stratum corneum and pilosebaceous units. |
| Bioavailability | Topical bioavailability: <5% for clindamycin (due to extensive metabolism in skin and low systemic absorption); benzoyl peroxide is essentially not absorbed systemically (<2%). |
| Onset of Action | Clinical improvement may be seen within 2 weeks of once-daily application, with maximal reduction in inflammatory and non-inflammatory lesions by 12 weeks. |
| Duration of Action | Duration of clinical effect persists with continued once-daily application. After discontinuation, acne lesions may recur without ongoing treatment. The keratolytic and antimicrobial effects are maintained over 24 hours with daily use. |
| Molecular Weight | Clindamycin: 424.98 Da; Benzoyl peroxide: 242.23 Da |
Apply a pea-sized amount to the entire face once daily in the evening, topical.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment; safety in severe renal impairment not established. |
| Liver impairment | No dose adjustment required for hepatic impairment; use caution in severe hepatic impairment. |
| Pediatric use | Approved for patients aged 12 years and older. For children 12-17 years: apply a pea-sized amount to the entire face once daily. |
| Geriatric use | No specific dose adjustment; use smallest effective amount due to increased risk of skin atrophy in elderly. |
| 1st trimester | Avoid. Topical clindamycin and benzoyl peroxide have limited data; however, systemic clindamycin is generally avoided in first trimester due to risk of congenital anomalies in animal studies. Use only if clearly needed. |
| 2nd trimester | Caution. Topical absorption minimal; however, safety not well established. Use only if potential benefit outweighs risk. |
| 3rd trimester | Caution. Avoid near term due to potential for infant botulism from systemic clindamycin exposure, though topical use is low risk. |
Clinical note
Comprehensive clinical and safety monograph for ACANYA (ACANYA).
| Placental transfer | Clindamycin crosses placenta (fetal serum 30-50% maternal levels). Benzoyl peroxide is not absorbed systemically, thus negligible placental transfer. |
| Breastfeeding | Topical application of clindamycin/benzoyl peroxide results in minimal systemic absorption. However, clindamycin appears in breast milk after systemic use; theoretical risk of infant gastrointestinal effects (diarrhea, colitis). Avoid application to breast area to prevent infant ingestion. Consider alternative therapy if prolonged or extensive use required. |
■ FDA Black Box Warning
There is no FDA black box warning for Acanya.
| Serious Effects |
Known hypersensitivity to clindamycin, benzoyl peroxide, or any component of the formulationHistory of enteritis, colitis, or antibiotic-associated colitis (especially from clindamycin)
| Precautions | Colitis: Clindamycin may cause pseudomembranous colitis; discontinue if diarrhea occurs., Skin irritation: Benzoyl peroxide may cause allergic contact dermatitis and photosensitivity; avoid excessive sun exposure., For external use only; avoid contact with eyes and mucous membranes. |
| Food/Dietary | No specific food interactions reported. Avoid concurrent use with other topical acne products unless directed. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | ACANYA (clindamycin phosphate 1.2% and benzoyl peroxide 5%) is for topical use. Systemic absorption is minimal; however, clindamycin is FDA Pregnancy Category C. Animal studies show no teratogenicity, but no adequate human studies exist. Benzoyl peroxide is Category C with unknown risk. First trimester: theoretical risk from systemic clindamycin if absorbed; second and third trimesters: minimal risk due to low absorption. No reported human teratogenicity for topical use. |
| Fetal Monitoring | No specific fetal monitoring required due to minimal systemic absorption. Monitor maternal skin for irritation or allergic reaction. If large areas treated, monitor for signs of systemic effects (e.g., diarrhea, pseudomembranous colitis from clindamycin). |
| Fertility Effects | No known effects on fertility in animal studies for clindamycin or benzoyl peroxide. No human data on fertility with topical use. Minimal systemic absorption suggests negligible impact. |
| Clinical Pearls |
| ACANYA (clindamycin 1.2% / benzoyl peroxide 2.5%) is a fixed-dose combination gel for acne vulgaris. Apply once daily; avoid excessive application. May bleach hair or colored fabrics. Counsel patients about skin dryness, peeling, and photosensitivity. Consider alternative if significant irritation occurs. |
| Patient Advice | Wash affected area gently before applying a thin layer once daily. · Avoid contact with eyes, mouth, lips, and mucous membranes. · May cause skin dryness, peeling, or redness; use moisturizer if needed. · Benzoyl peroxide can bleach hair or colored fabrics; avoid contact. · Use sunscreen daily as this product increases sun sensitivity. · If severe irritation or allergic reaction occurs, stop use and consult doctor. |